Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139291

Published: 2020

Journal Articles

PTPN11 mutations and Outcomes in Adult Patients with Acute Myeloid Leukemia

Klaus H. Metzeler, MD, Maja Rothenberg-Thurley, PhD, Dennis Görlich, PhD, Maria Cristina Sauerland, Annika Maria Dufour, PhD, Stephanie Schneider, PhD, Marion Subklewe, MD, Jan Braess, MD, Bernhard J. Wörmann, MD, Wolfgang E. Berdel, Prof., MD, Utz Krug, MD, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, MD, Tobias Herold, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137487

Published: 2020

Journal Articles

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Giulia Maggioni, MD, Cristina Astrid Tentori, MD, Maria Teresa Voso, MD, Sonja Heibl, MD, Klaus H. Metzeler, MD, Jan Moritz Middeke, MD, Joana Desterro, Maria Carmo-Fonseca, Erica Travaglino, Paola Fazi, MD, Alfonso Piciocchi, MS, Annika Maria Dufour, PhD, Jordi Esteve, Marta Pratcorona, MD, Valentina Mancini, MD, Federico Lussana, MD, Karsten Spiekermann, Christian Thiede, MD, Friedrich Stolzel, MD, Aida Botelho de Sousa, Mar Tormo, Pamela Acha, Montserrat Arnan, Nicola Fracchiolla, MD, Marcus Hentrich, Christoph Sippel, Bernhard Heilmeier, Marcos Lemos, Albertina Nunes, Sonia Matos, Marina Diaz, Ana Garrido, MD, David Gallardo, MD, Susana Vives, MD, Olga Salamero, Elisabetta Todisco, MDPhD, Claudia Basilico, MD, Francesco Passamonti, Sigrid Machherndl-Spandl, MD, Lisa Pleyer, Jorge Sierra, Francesc Solé, PhD, Matteo Giovanni Della Porta, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-140494

Published: 2020

Journal Articles

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136957

Published: 2020

Journal Articles

Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

Lea Pawlowsky, Bettina Brauchle, MSc, Maryam Kazerani Pasikhani, Ana Ogrinc Wagner, PhD, Veit Bücklein, MD, Felix S. Lichtenegger, MD, Roman Kischel, MD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Michael Andreeff, MD PhD, Naval G. Daver, MD, Michael von Bergwelt, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 1265.

https://doi.org/10.1182/blood-2019-122415

Published: 2019

Journal Articles

DNA Methylation Profiling of AML Reveals Epigenetic Subgroups with Distinct Clinical Outcome

Sebastian Vosberg, Paul Kerbs, MSc, Vindi Jurinovic, MSc, Klaus H. Metzeler, MD, Susanne Amler, PhD, Cristina Sauerland, Dennis Görlich, PhD, Wolfgang E. Berdel, MD, Jan Braess, MD, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, MD, Tobias Herold, MD, Philipp A. Greif, MD PD

Blood (2019) 134 (Supplement_1): 2715.

https://doi.org/10.1182/blood-2019-130047

Published: 2019

Journal Articles

Prospective Identification of Acute Myeloid Leukemia Patients Who Benefit from Gene-Expression Based Risk Stratification

Diego Chacon, PhD, Ali Braytee, PhD, Yizhou Huang, PhD, Julie Thoms, PhD, Shruthi Subramanian, BSc, Maria Cristina Sauerland, Stefan K. Bohlander, MD, Jan Braess, MD, Bernhard J. Wörmann, MD, Wolfgang E. Berdel, MD, Wolfgang Hiddemann, MD PhD, Bogdan Gabrys, PhD, Klaus H. Metzeler, MD, Tobias Herold, MD, John Pimanda, MBBS, PhD, Dominik Beck, PhD

Blood (2019) 134 (Supplement_1): 1397.

https://doi.org/10.1182/blood-2019-129519

Published: 2019

Journal Articles

Single Cell Clones Derived from a Patient's AML Xenograft Display Genetic and Functional Heterogeneity

Christina Maria Zeller, MSc, Daniel Richter, MSc, Binje Vick, PhD, Tobias Herold, MD, Johannes Bagnoli, Maja Rothenberg-Thurley, PhD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Wolfgang Enard, PhD, Irmela Jeremias, MD PhD

Blood (2019) 134 (Supplement_1): 1450.

https://doi.org/10.1182/blood-2019-127867

Published: 2019

Journal Articles

Loss of KDM6A Confers Drug Resistance in Acute Myeloid Leukemia

Sophie M. Stief, M.Sc., Anna-Li Hanneforth, Raphael Mattes, Sabrina Weser, M.Sc., Binje Vick, PhD, Michael D. Bartoschek, M.Sc., Helena Domínguez Moreno, M.Sc., Wen-Hsin Liu, PhD, Bianka Ksienzyk, Maja Rothenberg-Thurley, PhD, Hilmar Quentmeier, PhD, Wolfgang Hiddemann, Klaus H. Metzeler, MD, Gunnar Schotta, PhD, Sebastian Bultmann, PhD, Irmela Jeremias, MD PhD, Heinrich Leonhardt, PhD, Karsten Spiekermann, MD

Blood (2018) 132 (Supplement 1): 3935.

https://doi.org/10.1182/blood-2018-99-114959

Published: 2018

Journal Articles

Development of a Bifunctional Checkpoint Inhibitory T Cell Engager (CiTE) to Reverse Adaptive Immune Escape in AML

Monika Herrmann, PhD, Christina Krupka, PhD, Katrin Deiser, PhD, Bettina Lindl, Ralph Mocikat, MD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Sebastian Kobold, MD, Nadja Fenn, PhD, Karl-Peter Hopfner, PhD, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 4069.

https://doi.org/10.1182/blood-2018-99-119624

Published: 2018

Journal Articles

Minimal Residual Disease (MRD) Detection By Flow Cytometry Complements Molecular MRD Assessment in AML

Veit Bücklein, MD, Thomas Köhnke, MD, Frauke Schnorfeil, PhD, Klaus H. Metzeler, MD, Nikola P Konstandin, PhD, Annika Maria Dufour, PhD, Cristina Sauerland, Wolfgang Hiddemann, Karsten Spiekermann, MD, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 2753.

https://doi.org/10.1182/blood-2018-99-119065

Published: 2018

Journal Articles

Clonal Evolution of Relapsed CBFB/MYH11 Rearranged Acute Myeloid Leukemia (AML)

Sabrina Opatz, MD, Sebastian Vosberg, Bianka Ksienzyk, Sebastian Tschuri, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, Dr., Stephanie Schneider, PhD, Martin Neumann, Claudia D. Baldus, MD, Christian Thiede, MD, Jan Moritz Middeke, MD, Friedrich Stoelzel, Stefan K. Bohlander, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, PhD, Klaus H. Metzeler, MD, Philipp A. Greif, MD PD

Blood (2018) 132 (Supplement 1): 2772.

https://doi.org/10.1182/blood-2018-99-115881

Published: 2018

Journal Articles

Long Term AML Survivors Have Increased Mortality and High Prevalence of Clonal Hematopoiesis

Noa Chapal Ilani, PhD, Elisabeth Niemeyer, MD, Netta Mendelson Cohen, PhD, Yoni Moskovitz, PhD, Barak Oron, Amanda Mitchell, PhD, Mark D. Minden, MD PhD, Amos Tanay, PhD, Ran Balicer, MD PhD, Tamir Biezuner, PhD, Daniela Cilloni, MD PhD, Klaus H. Metzeler, MD, Yishai Ofran, MD, Nathali Kaushansky, PhD, Liran I. Shlush, MD PhD

Blood (2018) 132 (Supplement 1): 1287.

https://doi.org/10.1182/blood-2018-99-116599

Published: 2018

Journal Articles

AML Cells Express Exclusively the Long Isoform of LEF1 and Are Highly Vulnerable to Blockage of LEF1-β-Catenin Binding

Kristin Feder, MSc, Katrin Elisabeth Edmaier-Schröger, PhD, Nicole Kirsten, PhD, Linda Geisdorf, Naidu Vegi, PhD, Klaus H. Metzeler, MD, Michaela Feuring-Buske, MD, Christian Buske, MD

Blood (2018) 132 (Supplement 1): 3913.

https://doi.org/10.1182/blood-2018-99-116552

Published: 2018

Journal Articles

NPM1 Variant Allele Frequency and Outcomes in AML

Blood (2018) 132 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2018-99-112549

Published: 2018

Journal Articles

Aldehyde Dehydrogenase 2 ( ALDH2 ) Expression Predicts a Poor Prognosis in Acute Myeloid Leukemia

Linus Angenendt, Eike Bormann, Jan-Henrik Mikesch, Tobias Herold, Klaus H. Metzeler, MD, Stefan K. Bohlander, MD, Dennis Görlich, Maria Francisca Arteaga, Bernhard J. Wörmann, Georg Lenz, Wolfgang Hiddemann, Karsten Spiekermann, Utz Krug, Christina Sauerland, Wolfgang E. Berdel, Christoph Schliemann

Blood (2017) 130 (Supplement 1): 1386.

https://doi.org/10.1182/blood.V130.Suppl_1.1386.1386

Published: 2017

Journal Articles

Azacitidine Directly Acts on the Mesenchymal Stromal Cell Compartment in Myelodysplastic Syndromes to Alter Niche Function and Suppress Malignant Hematopoeitic Stem/Progenitor Cells

Catharina Wenk, MD, Anne-Kathrin Garz, MSc, Christina Huberle, MD, Sonja Grath, PhD, Denis Witham, Marie Weickert, Msc, Julia Niggemeyer, Msc, Judith Hecker, MD, Michele Kyncl, MSc, Catharina Müller-Thomas, MD, Christopher Mulholland, MSc, Robert A.J. Oostendorp, PhD, Klaus H. Metzeler, MD, Christian Peschel, MD, Katharina S Götze, MD

Blood (2017) 130 (Supplement 1): 1683.

https://doi.org/10.1182/blood.V130.Suppl_1.1683.1683

Published: 2017

Journal Articles

Interaction between FLT3 and CD99 in Acute Myeloid Leukemia

Vijaya Pooja Vaikari, MS, Sharon Wu, BS, Tian Zhang, BS, Sasha Kartman, Manal Abdi, Klaus H. Metzeler, MD, Mojtaba Akhtari, MD, Houda Alachkar, PharmD, PhD

Blood (2017) 130 (Supplement 1): 3786.

https://doi.org/10.1182/blood.V130.Suppl_1.3786.3786

Published: 2017

Journal Articles

Midostaurin Reduces Bite® Mediated Cytotoxicity Against Acute Myeloid Leukemia

Bettina Lindl, Christina Krupka, PhD, Tara Chapman-Arvedson, Roman Kischel, MD, Peter Kufer, MD, Sascha Haubner, MD, Felix S. Lichtenegger, MD, Thomas Koehnke, MD, Klaus H. Metzeler, MD, Nikola Konstandin, PhD, Karsten Spiekermann, Wolfgang Hiddemann, MD PhD, Marion Subklewe, MD

Blood (2017) 130 (Supplement 1): 2656.

https://doi.org/10.1182/blood.V130.Suppl_1.2656.2656

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Detection By Flow Cytometry during Aplasia and Post-Induction Is an Independent Prognostic Parameter for Relapse-Free Survival in AML

Veit Bücklein, MD, Thomas Koehnke, MD, Sandra Rechkemmer, Frauke Schnorfeil, PhD, Stephanie Schneider, PhD, Maja Rothenberg-Thurley, PhD, Klaus H. Metzeler, MD, Cristina Sauerland, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, Marion S. Subklewe, MD

Blood (2017) 130 (Supplement 1): 5081.

https://doi.org/10.1182/blood.V130.Suppl_1.5081.5081

Published: 2017

NARROW

A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia

PTPN11 mutations and Outcomes in Adult Patients with Acute Myeloid Leukemia

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

DNA Methylation Profiling of AML Reveals Epigenetic Subgroups with Distinct Clinical Outcome

Prospective Identification of Acute Myeloid Leukemia Patients Who Benefit from Gene-Expression Based Risk Stratification

Single Cell Clones Derived from a Patient's AML Xenograft Display Genetic and Functional Heterogeneity

Loss of KDM6A Confers Drug Resistance in Acute Myeloid Leukemia

Development of a Bifunctional Checkpoint Inhibitory T Cell Engager (CiTE) to Reverse Adaptive Immune Escape in AML

Minimal Residual Disease (MRD) Detection By Flow Cytometry Complements Molecular MRD Assessment in AML

Clonal Evolution of Relapsed CBFB/MYH11 Rearranged Acute Myeloid Leukemia (AML)

Long Term AML Survivors Have Increased Mortality and High Prevalence of Clonal Hematopoiesis

AML Cells Express Exclusively the Long Isoform of LEF1 and Are Highly Vulnerable to Blockage of LEF1-β-Catenin Binding

NPM1 Variant Allele Frequency and Outcomes in AML

Aldehyde Dehydrogenase 2 ( ALDH2 ) Expression Predicts a Poor Prognosis in Acute Myeloid Leukemia

Azacitidine Directly Acts on the Mesenchymal Stromal Cell Compartment in Myelodysplastic Syndromes to Alter Niche Function and Suppress Malignant Hematopoeitic Stem/Progenitor Cells

Interaction between FLT3 and CD99 in Acute Myeloid Leukemia

Midostaurin Reduces Bite® Mediated Cytotoxicity Against Acute Myeloid Leukemia

Minimal Residual Disease (MRD) Detection By Flow Cytometry during Aplasia and Post-Induction Is an Independent Prognostic Parameter for Relapse-Free Survival in AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only